

ExAblate[®] 2000

Most people are familiar with ultrasound as a diagnostic tool. Now ExAblate[®] 2000, a Magnetic Resonance guided Focused Ultrasound system, unleashes the therapeutic potential of ultrasound by integrating it with the precision guidance and monitoring provided by MR imaging.

Description

- ExAblate is a Magnetic Resonance guided Focused Ultrasound system which uses a Magnetic Resonance Imaging (MRI) scanner to identify tissues in the body and assist in planning the treatment. During the procedure, delivery of focused ultrasound energy is guided and controlled using MR thermal imaging.
- Thermal imaging feedback allows the physician to monitor and adjust the treatment to ensure that:
 - the targeted tumor is fully treated
 - all other tissue is avoided
- Works exclusively with the GE 1.5 Tesla and 3.0 Tesla MRI systems
- Awarded the CE Mark and ISO 9001 certification in 2002
- Awarded the 2004 European Union's IST grand prize for innovation and potential to benefit mankind, a Bronze Medal and Second Place in the Medical Category of *The Wall Street Journal's* 2004 Technology Innovation Awards, and *Advanced Imaging's* 2005 Solutions of the Year. InSightec was selected for the Red Herring 100 Europe 2007 list of the top privately-held technology companies in Europe, the Middle East and Africa (EMEA) and recently one of the World Economic Forum Technology Pioneer 2008.

Benefits of ExAblate

- Non-invasive surgery, no incision required, no anesthesia
- Outpatient procedure – no hospital stay
- Low rate of complications
- Return to normal activity within one to two days

How it Works

- MR imaging allows physician to locate diseased tissue or tumor
- High-intensity ultrasound energy is focused to a small volume within the tumor
- Focused ultrasound waves thermally ablate (destroy) tissue
- Process is repeated until tumor is destroyed
- Body disposes of destroyed tissue as part of normal function

**FDA
Approved**

In October 2004, the U.S. Food and Drug Administration approved the ExAblate system for treatment of symptomatic uterine fibroids. The FDA expedited the approval because the ExAblate 2000 system “offers significant advantages over existing treatments for uterine fibroids,” according to the agency.

**Positive
Clinical
Results**

ExAblate offered women sustained relief from uterine fibroid symptoms for up to two years, with a low incidence of side effects, according to a study published in the August 2007 issue of *Obstetrics and Gynecology*. The 359-patient Mayo Clinic-led collaborative study also showed that destroying as much of the fibroid as possible leads to the most durable symptom relief with 85% of the participants experiencing symptom improvement after one year.

**Additional
Applications
Under
Investigation**

- Bone metastases
- Breast cancer
- Brain tumors
- Liver tumors
- Prostate cancer

For more information, contact:

InSightec Ltd.
P.O. Box 2059
Tirat Carmel 39120, Israel
Tel: +972-4-813-1313
Fax: +972-4-813-1322
Email: info@insightec.com

For media inquiries, contact:

Fern Lazar
Lazar Partners, Ltd.
Tel: (212) 867-1762
Email: flazar@lazarpartners.com flazar@lazarpartners.com

For more information, please visit <http://www.insightec.com>

InSightec Ltd.
P.O. Box 2059
Tirat Carmel 39120 Israel
(+972) 4 8131313
www.insightec.com